Humira, Biosimilars, and Autoimmune Drugs on Medicare

The biologic drugs used to treat autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn's disease are some of the most effective and most expensive medications in modern medicine. Humira, Enbrel, and Stelara can carry list prices in the thousands of dollars per month. For Medicare beneficiaries who depend on them, the questions that matter are which part of Medicare pays, how much of that cost lands on you, and how newer lower-cost biosimilars fit in. The answers have improved a lot recently, especially with the arrival of the annual out-of-pocket cap.

Bryce's Take

Specialty biologics are where I see the biggest before-and-after difference from the $2,000 cap. I had clients on Humira and similar drugs paying five figures a year out of pocket. Now the worst case is capped, and many of them hit that cap in the first couple of months and coast the rest of the year. The two things I always check are whether your specific biologic is on the plan at a workable tier and whether there is a step-therapy hurdle. If you are on one of these drugs, let us make sure your plan actually fits it.

The Part B vs Part D split for biologics

How a biologic is covered depends largely on how it is administered. Self-injected biologics that you give yourself at home, like Humira and Enbrel, are typically covered under Part D, your prescription drug coverage. Biologics that are infused or injected in a doctor's office or clinic are often covered under Part B, the medical side, because they are administered by a provider. This distinction changes what you pay and how it is calculated, and it is one of the more confusing parts of autoimmune drug coverage. If you are switching from an infused to a self-injected version of a similar drug, or vice versa, your coverage pathway can change with it.

The specialty tier and high coinsurance

Under Part D, biologics like Humira, Enbrel, and Stelara almost always land on the specialty tier, the highest cost tier on a plan's formulary. Specialty-tier drugs are usually subject to coinsurance, meaning you pay a percentage of the drug's cost rather than a flat copay. On a drug that costs several thousand dollars a month, that percentage adds up fast. This is precisely why the annual out-of-pocket cap, discussed below, has been such a meaningful change for people on these drugs.

Biosimilars: lower-cost versions of the biologic

A biosimilar is an FDA-approved biological drug that is highly similar to an existing reference biologic, with no clinically meaningful differences in safety or effectiveness. Biosimilars of Humira and other biologics are now available and are typically priced lower than the original. Part D plans often place biosimilars on lower tiers than the reference biologic, which can reduce your cost-sharing. Plans may also prefer a biosimilar or use step therapy, meaning they may ask you to try the biosimilar first. Whether a biosimilar is right for you is a clinical decision for your prescriber, so ask whether one is appropriate for your condition.

Step therapy and prior authorization

Biologics frequently come with utilization rules. Step therapy, sometimes called fail-first, means a plan may require you to try a preferred or lower-cost drug, such as a biosimilar, before it covers the one your doctor originally chose. Prior authorization means the plan requires clinical documentation before it will cover the drug at all. Both can delay the start of therapy. Knowing these rules exist, starting the paperwork early, and understanding your appeal rights if you are denied are important when you are on a specialty biologic.

The $2,000 cap matters enormously here

For no group of drugs does the annual out-of-pocket cap matter more than for specialty biologics. Since 2025, your total cost-sharing for covered Part D drugs cannot exceed $2,000 in a plan year. For someone paying specialty-tier coinsurance on a drug that costs thousands per month, that used to mean many thousands of dollars out of pocket every year. Now, once you hit $2,000, you pay nothing more for covered drugs for the rest of the year. Because expensive biologics push you toward that cap quickly, many people on them reach it early in the year and are protected the rest of the way.

Choosing coverage for your biologic

The right plan for someone on a biologic is the one that covers that specific drug, or a suitable biosimilar, at the best available terms, and that does not bury it behind step therapy you cannot satisfy. During the Annual Enrollment Period, compare plans on your exact biologic, check its tier placement and any utilization rules, and factor in the $2,000 cap. If your drug is infused in a clinic under Part B, the calculus shifts toward your medical coverage and any Medigap or Advantage out-of-pocket structure. This is a comparison worth doing carefully, and one I do with clients regularly.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.